|Other Names||Neuroblastoma suppressor of tumorigenicity 1, DAN domain family member 1, Protein N03, Zinc finger protein DAN, NBL1, DAN, DAND1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6217a was selected from the C-term region of human NBL1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Possible candidate as a tumor suppressor gene of neuroblastoma. May play an important role in preventing cells from entering the final stage (G1/S) of the transformation process.|
|Tissue Location||Most abundant in normal lung and meningioma.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
NBL1 is a transcription factor that may function as an inhibitor or repressor in cell growth and/or maintenance, and plays a role in the negative regulation of the cell cycle. It has a possible tumor suppressive activity when over expressed. Alternative splicing occurs at this locus and two transcript variants encoding the same protein have been identified.
Shinbo, J., et al., Biochem. Biophys. Res. Commun. 295(2):501-507 (2002).Ozaki, T., et al., DNA Cell Biol. 16(9):1031-1039 (1997).Caron, H., et al., Hum. Mol. Genet. 4(4):535-539 (1995).White, P.S., et al., Proc. Natl. Acad. Sci. U.S.A. 92(12):5520-5524 (1995).Enomoto, H., et al., Oncogene 9(10):2785-2791 (1994).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.